GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kintor Pharmaceutical 9939.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.40

+1.45%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Kintor Pharmaceutical

Its shares trade on HKEX under the ticker 9939.HK. It has been listed since 22 May 2020. In the fiscal year to 31 December 2023, it reported a net loss of CN¥1.06bn.

Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which focuses on the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-05-22. The firm is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The firm are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 May 2020
Employees
172

Leadership

Pay as last reported

  • Dr. Tong YouzhiExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥2.7m
  • Mr. Ming Ming CheungChief Financial Officer, Joint Company Secretary
  • Ms. Qun LuChief Technology Officer, Executive Director, since 2021
  • Dr. Ruo XuVice President - Chemistry
  • Dr. Jianfei YangVice President - Biologics
  • Mr. Liandong MaVice President - Research and Development
  • Mr. Jiawen HanVice President - Business Development
  • Mr. Juping ShenDeputy General Manager
  • Mr. Xiang NiChief Medical Officer, Executive Director, since 2023
  • Mr. Wai Chiu WongJoint Company Secretary
  • Ms. Wei GeqiNon-Executive Director
  • Mr. Gao WeipengNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Kintor Pharmaceutical Ltd possesses several strengths that contribute to its competitive advantage:

Weaknesses

  • Despite its strengths, Kintor Pharmaceutical Ltd also faces certain weaknesses that may hinder its growth:

Opportunities

  • Kintor Pharmaceutical Ltd can capitalize on the following opportunities to further advance its business:

Threats

  • Alongside opportunities, Kintor Pharmaceutical Ltd should be cautious of the following threats that may impact its operations:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.